Key result
NSTEMI-OMI carries a 30-day mortality risk similar to STEMI.
Why the study?
Although acute total coronary occlusion is assumed to correspond to STEMI, growing evidence suggests the STEMI/NSTEMI paradigm is inadequate for guiding emergency revascularization.
Does the angiographic diagnosis of occlusion myocardial infarction (OMI) in NSTEMI patients predict 30-day mortality comparable to STEMI patients?
Cohort (n=1,540)
Does the angiographic diagnosis of occlusion myocardial infarction (OMI) in NSTEMI patients predict 30-day mortality comparable to STEMI patients?
Effect estimate: HR 0.75 (95% CI 0.51-1.11)
p-value: p=0.146
NSTEMI patients with angiographically confirmed occlusion myocardial infarction have a 30-day mortality risk similar to STEMI patients, suggesting the current STEMI/NSTEMI paradigm may inadequately triage patients needing urgent reperfusion.
NSTEMI-OMI was associated with STEMI-comparable 30-day mortality; leaves open whether OMI criteria warrant prospective trials to refine reperfusion triage.
Abstract Background It is commonly assumed that acute total occlusion of the infarct-related artery corresponds to the diagnosis of ST-elevation myocardial infarction (STEMI), yet growing evidence suggests that the ST-elevation/non–ST-elevation myocardial infarction (NSTEMI) paradigm is inadequate for guiding emergency revascularization. Methods We conducted a retrospective study and assessed the association of occlusion/non-occlusion myocardial infarction (OMI/NOMI) angiographic diagnosis with short-term mortality, compared with the ECG diagnosis of STEMI/NSTEMI. Data from 1540 patients with acute myocardial infarction treated with percutaneous cardiac intervention (PCI) (68 % males, 40.3 % with initial diagnosis of STEMI, 51.6 % with final diagnosis of OMI) were analyzed. OMI was defined as MI with Thrombolysis In Myocardial Infarction (TIMI) 0–2 flow before revascularization. Primary aim was to compare 30-day mortality risk between NSTEMI-OMI and STEMI. Results Among patients initially identified as NSTEMI, 37.3 % had OMI. Although the infarct size as assessed by peak troponin hs-cTnT was smaller in NSTEMI-OMI than in STEMI patients (median (IQR): 17497.16 (3596.56–25,000.10) vs 25,000.1 (10,893.41–25,000.10) ng/L; p < 0.001) however, NSTEMI-OMI patients did not differ in 30-day mortality risk in comparison to STEMI patients (HR 0.75, 95 %CI 0.51–1.11, p = 0.146) and had significantly higher mortality risk than NSTEMI-NOMI patients (HR 2.4, 95 %CI 1.46–4.01, p = 0.001). Conclusions The high prevalence of OMI among NSTEMI patients and their unfavorable outcomes clearly demonstrate that the assessment of acute myocardial infarction should not rely solely on ST-segment elevation on admission ECG, as the STEMI/NSTEMI classification may miss patients with acute coronary occlusion who require urgent reperfusion.
No takes yet. Share an insight, caveat, or question.
Terlecki et al. (2025) conducted a cohort in Acute myocardial infarction (n=1,540). NSTEMI-OMI vs. STEMI was evaluated on 30-day mortality risk (HR 0.75, 95% CI 0.51-1.11, p=0.146). Patients with NSTEMI and angiographically confirmed occlusion myocardial infarction (NSTEMI-OMI) had a 30-day mortality risk similar to STEMI patients (HR 0.75; 95% CI 0.51-1.11; p=0.146).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: